$BIIB News

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Biogen Says Fourteen Abstracts Highlighting Data From Nephrology Portfolio, Including EMPAVELI And Investigational Felzartamab, Accepted For Presentation At 63rd ERA And 2026 ATC

Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration Pipeline

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

UCB and Biogen Report Late-Stage Lupus Trial Results for Experimental Drug

Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report?

RBC Capital Maintains Outperform on Biogen, Raises Price Target to $227

Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

Parkinson’s drug from Biogen, Denali comes up short

BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus

Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price

Evercore ISI Group Reinstates Outperform on Biogen

Biogen completes $5.3B Apellis Pharmaceuticals acquisition